Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
100.00%
Operating Margin
54.41%
Net Margin
-99.13%
Efficiency Metrics
Revenue per Expense Ratio
2.19
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
-73.93%
Income Tax Rate
-1,346,764,500.0%
EPS
-1.4500000000
Balance Sheet Analysis
Current Ratio
0.13
Cash Ratio
0.00
Working Capital
$-6.37M
Debt to Equity
0.19
Debt to Assets
14.63%
Equity Ratio
77.23%
Cash Flow Analysis
Operating Cash Flow Ratio
575.38%
Free Cash Flow Ratio
575.38%
CapEx to Revenue
0.00%
Dividends Paid
$31.78M
Stock Buybacks
$18.72M
Total Shareholder Returns
$50.50M
Cash Position Change
8,521,475,800.0%
Key Takeaways (2023 FY)
Revenue declined by 85.078745446925%, indicating potential market challenges
Increased dividend payments by 4.62%
Detailed Growth Metrics
Core Performance
Revenue
-85.08%
Net Income
-115.13%
EPS
-116.65%
Operating Income
-92.00%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
666.69%
Operating Cash Flow
105.27%
Free Cash Flow
105.27%
Balance Sheet Health
Assets
-20.96%
Debt
-35.78%
Book Value per Share
-6.17%
Inventory
0.00%
Shareholder Returns
Dividends per Share
4.62%
Shares Outstanding
-9.20%
Long Term Trends
3Y Revenue/Share
103.52%
5Y Revenue/Share
-79.07%
3Y Dividend/Share
39.60%
5Y Dividend/Share
-74.30%